David E Root

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/58708/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for <i>CSNK1A1</i> in clonal expansion. Blood Advances, 2022, 6, 1780-1796.	5.2	7
2	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications, 2022, 13, 604.	12.8	22
3	Systematic identification of biomarker-driven drug combinations to overcome resistance. Nature Chemical Biology, 2022, 18, 615-624.	8.0	14
4	Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nature Cancer, 2022, 3, 681-695.	13.2	21
5	Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state. Nature Communications, 2022, 13, .	12.8	15
6	Structure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex. Nature, 2022, 609, 408-415.	27.8	28
7	Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood, 2021, 137, 2360-2372.	1.4	26
8	Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nature Biotechnology, 2021, 39, 697-704.	17.5	85
9	LKB1/ <i>STK11</i> Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discovery, 2021, 11, 1398-1410.	9.4	29
10	Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. Cancer Discovery, 2021, 11, 2282-2299.	9.4	21
11	Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nature Genetics, 2021, 53, 1664-1672.	21.4	61
12	Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nature Structural and Molecular Biology, 2020, 27, 92-104.	8.2	30
13	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 5974-5989.	7.0	87
14	A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics, 2020, 19, 1423-1435.	4.1	14
15	A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. Nature Communications, 2020, 11, 2707.	12.8	11
16	A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	12.6	265
17	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	12.8	37
18	The landscape of cancer cell line metabolism. Nature Medicine, 2019, 25, 850-860.	30.7	350

DAVID E ROOT

#	Article	lF	CITATIONS
19	A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Research, 2019, 79, 2352-2366.	0.9	34
20	WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature, 2019, 568, 551-556.	27.8	253
21	Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nature Communications, 2019, 10, 5817.	12.8	160
22	Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discovery, 2019, 9, 230-247.	9.4	119
23	Pooled Lentiviralâ€Delivery Genetic Screens. Current Protocols in Molecular Biology, 2018, 121, 32.1.1-32.1.21.	2.9	20
24	Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens. Nature Biotechnology, 2018, 36, 179-189.	17.5	216
25	Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nature Communications, 2018, 9, 4610.	12.8	290
26	Mutational processes shape the landscape of TP53 mutations in human cancer. Nature Genetics, 2018, 50, 1381-1387.	21.4	334
27	Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics, 2018, 50, 1240-1246.	21.4	199
28	The Canonical Wnt Pathway Drives Macropinocytosis in Cancer. Cancer Research, 2018, 78, 4658-4670.	0.9	75
29	Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nature Communications, 2017, 8, 15403.	12.8	93
30	Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nature Genetics, 2017, 49, 1779-1784.	21.4	1,436
31	Defining a Cancer Dependency Map. Cell, 2017, 170, 564-576.e16.	28.9	1,794
32	A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell, 2017, 171, 1437-1452.e17.	28.9	2,281
33	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. Journal of Clinical Investigation, 2017, 128, 446-462.	8.2	117
34	Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants. Cell Reports, 2016, 17, 1171-1183.	6.4	119
35	High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell, 2016, 30, 214-228.	16.8	171
36	A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative Phosphorylation. Cell Metabolism, 2016, 24, 875-885.	16.2	244

DAVID E ROOT

#	Article	IF	CITATIONS
37	Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nature Biotechnology, 2016, 34, 184-191.	17.5	3,168
38	<i>MTAP</i> deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science, 2016, 351, 1214-1218.	12.6	396
39	A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell, 2015, 27, 397-408.	16.8	150
40	Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. Journal of Experimental Medicine, 2014, 211, 605-612.	8.5	79
41	Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18661-18666.	7.1	46
42	Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science, 2014, 343, 84-87.	12.6	4,210
43	Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation. Nature Biotechnology, 2014, 32, 1262-1267.	17.5	1,351
44	KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell, 2014, 158, 171-184.	28.9	608
45	Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Scientific Data, 2014, 1, 140035.	5.3	328
46	A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature, 2013, 504, 138-142.	27.8	401
47	A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition. Cancer Discovery, 2013, 3, 350-362.	9.4	299
48	A public genome-scale lentiviral expression library of human ORFs. Nature Methods, 2011, 8, 659-661.	19.0	477
49	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12372-12377.	7.1	383
50	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010, 468, 968-972.	27.8	1,325
51	Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 2008, 451, 335-339.	27.8	850